Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
CD19 is the most promising target for developing chimeric-antigen receptor (CAR) T cells against B-cell leukemic cancer. Currently, two CAR-T-cell products, Kymriah and Yescarta, are approved for leukemia patients, and various anti-CD19 CAR T cells are undergoing clinical trial. Most of these anti-C...
Main Authors: | Chung Hyo Kang, Yeongrin Kim, Heung Kyoung Lee, So Myoung Lee, Hye Gwang Jeong, Sang Un Choi, Chi Hoon Park |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/23/9163 |
Similar Items
-
INCREASING OF THE EXPRESSION OF RECOMBINANT scFv-ANTIBODIES EFFICIENCY
by: O.V. Galkin, et al.
Published: (2017-10-01) -
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
by: Nardos G. Tassew, et al.
Published: (2013-04-01) -
RECOGNITION OF Mycobacterium tuberculosis ANTIGENS MPT63 AND MPT83 WITH MURINE POLYCLONAL AND scFv ANTIBODIES
by: A. A. Siromolot, et al.
Published: (2018-04-01) -
Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals
by: Manuela Berto Pucca, et al.
Published: (2011-03-01) -
Anti-Idiotype scFv Localizes an Autoepitope in the Globular Domain of C1q
by: Nadezhda Todorova, et al.
Published: (2021-08-01)